Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Volitionrx (VNRX) Operating Income (2018 - 2025)

Volitionrx filings provide 9 years of Operating Income readings, the most recent being -$4.8 million for Q4 2025.

  • On a quarterly basis, Operating Income rose 16.66% to -$4.8 million in Q4 2025 year-over-year; TTM through Dec 2025 was -$21.7 million, a 19.56% increase, with the full-year FY2025 number at -$21.7 million, up 19.56% from a year prior.
  • Operating Income hit -$4.8 million in Q4 2025 for Volitionrx, up from -$5.1 million in the prior quarter.
  • In the past five years, Operating Income ranged from a high of -$4.8 million in Q4 2025 to a low of -$9.5 million in Q2 2023.
  • Median Operating Income over the past 5 years was -$7.6 million (2021), compared with a mean of -$7.2 million.
  • Biggest five-year swings in Operating Income: crashed 67.89% in 2021 and later surged 34.14% in 2025.
  • Volitionrx's Operating Income stood at -$8.8 million in 2021, then rose by 8.81% to -$8.0 million in 2022, then decreased by 9.11% to -$8.7 million in 2023, then soared by 33.86% to -$5.8 million in 2024, then grew by 16.66% to -$4.8 million in 2025.
  • The last three reported values for Operating Income were -$4.8 million (Q4 2025), -$5.1 million (Q3 2025), and -$6.3 million (Q2 2025) per Business Quant data.